Domain To Bring First Wholly Owned GCPR Asset Into Clinic
After Building Reputation Through Partnerships
Executive Summary
The French firm is going it alone for the first time with a planned Phase I trial for its lead EP4 receptor antagonist in cancer after years of sharing its technology and GCPR expertise with big pharma.
You may also be interested in...
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.
Geron’s Imetelstat Headed To US FDA Advisory Committee For MDS
Geron’s telomerase inhibitor will also get standard review for transfusion-dependent anemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS), suggesting FDA reviewers may be less bullish on imetelstat’s clinical data than analysts have been.